• Home

Home > Medical Reference > Complementary Medicine

•    Related Program - Center for Integrative Medicine

Naphazoline and Antazoline

• Pronunciation
• U.S. Brand Names
• Synonyms
• Generic Available
• Canadian Brand Names
• Use
• Pregnancy Risk Factor
• Contraindications
• Adverse Reactions
• Drug Interactions
• Stability
• Dosage
• Patient Education
• Nursing Implications
• Dental Health: Effects on Dental Treatment
• Dental Health: Vasoconstrictor/Local Anesthetic Precautions
• Mental Health: Effects on Mental Status
• Mental Health: Effects on Psychiatric Treatment
• Dosage Forms
• International Brand Names

Pronunciation

(naf AZ oh leen & an TAZ oh leen)

U.S. Brand Names

Vasocon-A® [OTC]

Synonyms

Antazoline and Naphazoline

Generic Available

No

Canadian Brand Names

Albalon®-A Liquifilm; Vasocon-A®

Use

Topical ocular congestion, irritation and itching

Pregnancy Risk Factor

C

Contraindications

Hypersensitivity to naphazoline, antazoline, or any component of the formulation; angle-closure glaucoma

Adverse Reactions

Frequency not defined.

Cardiovascular: Systemic cardiovascular stimulation, hypertension

Central nervous system: Nervousness, dizziness, headache

Gastrointestinal: Nausea

Local: Transient stinging

Neuromuscular & skeletal: Weakness

Ocular: Mydriasis, increased intraocular pressure, blurred vision

Respiratory: Nasal mucosa irritation, dryness, rebound congestion

Miscellaneous: Diaphoresis

Drug Interactions

MAO inhibitors (exaggerated adrenergic effects may result)

Stability

Store in tight, light-resistant containers

Dosage

Ophthalmic: 1-2 drops every 3-4 hours

Patient Education

Do not use discolored solutions

Nursing Implications

Do not use discolored solutions

Dental Health: Effects on Dental Treatment

No significant effects or complications reported

Dental Health: Vasoconstrictor/Local Anesthetic Precautions

No information available to require special precautions

Mental Health: Effects on Mental Status

May cause nervousness or dizziness

Mental Health: Effects on Psychiatric Treatment

TCAs and MAO inhibitors may potentiate the pressor response of decongestants; monitor for changes in response

Dosage Forms

Solution, ophthalmic: Naphazoline hydrochloride 0.05% and antazoline phosphate 0.5% (15 mL) [contains benzalkonium chloride]

International Brand Names

Albalon®-A Liquifilm (CA); Vasocon-A® (CA)

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.